Cliff Asness's TMO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 144,752 shares of Thermo Fisher Scientific Inc. (TMO) worth $83.88 M, representing 0.04% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in TMO, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2018, adding 624,602 shares. Largest reduction occurred in Q1 2020, reducing 675,845 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Thermo Fisher Scientific (TMO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Thermo Fisher Scientific (TMO) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -10,856 | Reduce 6.98% | 144,752 | $579.45 |
| Q3 2025 | +46,918 | Add 43.17% | 155,608 | $465.48 |
| Q2 2025 | -100,575 | Reduce 48.06% | 108,690 | $405.46 |
| Q1 2025 | -11,937 | Reduce 5.40% | 209,265 | $489.13 |
| Q4 2024 | +9,797 | Add 4.63% | 221,202 | $520.23 |
| Q3 2024 | +113,253 | Add 115.39% | 211,405 | $611.86 |
| Q2 2024 | +15,009 | Add 18.05% | 98,152 | $553.00 |
| Q1 2024 | -25,752 | Reduce 23.65% | 83,143 | $578.59 |
| Q4 2023 | -48,844 | Reduce 30.97% | 108,895 | $530.79 |
| Q3 2023 | -20,937 | Reduce 11.72% | 157,739 | $506.17 |
| Q2 2023 | -47,989 | Reduce 21.17% | 178,676 | $519.65 |
| Q1 2023 | +16,194 | Add 7.69% | 226,665 | $569.93 |
| Q4 2022 | -34,081 | Reduce 13.94% | 210,471 | $548.99 |
| Q3 2022 | -31,617 | Reduce 11.45% | 244,552 | $507.19 |
| Q2 2022 | -434,559 | Reduce 61.14% | 276,169 | $533.59 |
| Q1 2022 | -235,464 | Reduce 24.89% | 710,728 | $590.65 |
| Q4 2021 | -167,591 | Reduce 15.05% | 946,192 | $667.24 |
| Q3 2021 | +49,310 | Add 4.63% | 1.11 M | $571.33 |
| Q2 2021 | -38,546 | Reduce 3.49% | 1.06 M | $504.47 |
| Q1 2021 | +302,402 | Add 37.77% | 1.1 M | $455.20 |
| Q4 2020 | +125,124 | Add 18.52% | 800,617 | $461.60 |
| Q3 2020 | +125,333 | Add 22.78% | 675,493 | $439.08 |
| Q2 2020 | -15,058 | Reduce 2.66% | 550,160 | $352.69 |
| Q1 2020 | -675,845 | Reduce 54.46% | 565,218 | $283.60 |
| Q4 2019 | -417,282 | Reduce 25.16% | 1.24 M | $324.53 |
| Q3 2019 | -483,126 | Reduce 22.56% | 1.66 M | $290.96 |
| Q2 2019 | +598,230 | Add 38.76% | 2.14 M | $290.25 |
| Q1 2019 | -372,305 | Reduce 19.44% | 1.54 M | $270.95 |
| Q4 2018 | +416,123 | Add 27.75% | 1.92 M | $223.79 |
| Q3 2018 | +624,602 | Add 71.40% | 1.5 M | $244.08 |
| Q2 2018 | +427,284 | Add 95.47% | 874,821 | $207.14 |
| Q1 2018 | +60,971 | Add 15.77% | 447,537 | $206.46 |
| Q4 2017 | +180,385 | Add 87.49% | 386,566 | $189.88 |
| Q3 2017 | +22,468 | Add 12.23% | 206,181 | $189.20 |
| Q2 2017 | +16,760 | Add 10.04% | 183,713 | $174.47 |
| Q1 2017 | -3,440 | Reduce 2.02% | 166,953 | $153.60 |
| Q4 2016 | +1,368 | Add 0.81% | 170,393 | $141.10 |
| Q3 2016 | -58,761 | Reduce 25.80% | 169,025 | $159.06 |
| Q2 2016 | +52,097 | Add 29.65% | 227,786 | $147.76 |
| Q1 2016 | -72,607 | Reduce 29.24% | 175,689 | $141.59 |
| Q4 2015 | -31,793 | Reduce 11.35% | 248,296 | $141.85 |
| Q3 2015 | +58,622 | Add 26.47% | 280,089 | $122.28 |
| Q2 2015 | +88,374 | Add 66.40% | 221,467 | $129.76 |
| Q1 2015 | -52,984 | Reduce 28.47% | 133,093 | $134.34 |
| Q4 2014 | +16,543 | Add 9.76% | 186,077 | $125.29 |
| Q3 2014 | -79,940 | Reduce 32.04% | 169,534 | $121.70 |
| Q2 2014 | -44,000 | Reduce 14.99% | 249,474 | $118.00 |
| Q1 2014 | +54,400 | Add 22.75% | 293,474 | $120.24 |
| Q4 2013 | +26,037 | Add 12.22% | 239,074 | $111.35 |
| Q3 2013 | -122,971 | Reduce 36.60% | 213,037 | $92.15 |
| Q2 2013 | +336,008 | Add 0.00% | 336,008 | $84.63 |
| Q4 2012 | +652,994 | Add 0.00% | 652,994 | $63.78 |
Cliff Asness's Thermo Fisher Scientific Investment FAQs
Cliff Asness first purchased Thermo Fisher Scientific Inc. (TMO) in Q4 2012, acquiring 652,994 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Thermo Fisher Scientific Inc. (TMO) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Thermo Fisher Scientific Inc. (TMO) was in Q4 2012, adding 652,994 shares worth $41.65 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 144,752 shares of Thermo Fisher Scientific Inc. (TMO), valued at approximately $83.88 M.
As of the Q4 2025 filing, Thermo Fisher Scientific Inc. (TMO) represents approximately 0.04% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Thermo Fisher Scientific Inc. (TMO) was 2,141,471 shares, as reported at the end of Q2 2019.